Comparative Adverse Kidney Outcomes in Women Receiving Raloxifene and Denosumab in a Real-World Setting.

Biomedicines · 2022 · PMC9313089 · PMID 35884799

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

As an SERM, raloxifene may exert renoprotective effects similar to estrogen, as seen in our subgroup analysis, and almost all patients using raloxifene showed a trend of decreasing CKD progression, despite differences in age, baseline eGFR, and AKI occurrence.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.